HomeCompareVMCS vs JNJ

VMCS vs JNJ: Dividend Comparison 2026

VMCS yields 27397.26% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VMCS wins by $1.1972107461873825e+21M in total portfolio value
10 years
VMCS
VMCS
● Live price
27397.26%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.1972107461873825e+21M
Annual income
$1,188,675,931,216,516,700,000,000,000.00
Full VMCS calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — VMCS vs JNJ

📍 VMCS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVMCSJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VMCS + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VMCS pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VMCS
Annual income on $10K today (after 15% tax)
$2,328,767.12/yr
After 10yr DRIP, annual income (after tax)
$1,010,374,541,534,039,100,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, VMCS beats the other by $1,010,374,541,534,039,100,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VMCS + JNJ for your $10,000?

VMCS: 50%JNJ: 50%
100% JNJ50/50100% VMCS
Portfolio after 10yr
$598605373093691260928.00M
Annual income
$594,337,965,608,258,360,000,000,000.00/yr
Blended yield
99.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VMCS
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VMCS buys
0
JNJ buys
0
No recent congressional trades found for VMCS or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVMCSJNJ
Forward yield27397.26%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1.1972107461873825e+21M$30.5K
Annual income after 10y$1,188,675,931,216,516,700,000,000,000.00$4,749.88
Total dividends collected$1.1966488951365923e+21M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VMCS vs JNJ ($10,000, DRIP)

YearVMCS PortfolioVMCS Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,750,426$2,739,726.03$10,594$274.49+$2.74MVMCS
2$707,187,234$704,244,277.92$11,294$360.69+$707.18MVMCS
3$169,985,380,233$169,228,689,893.21$12,133$476.91+$169985.37MVMCS
4$38,197,967,914,920$38,016,083,558,069.93$13,156$635.42+$38197967.90MVMCS
5$8,024,720,272,857,223$7,983,848,447,188,260.00$14,432$854.61+$8024720272.84MVMCS
6$1,576,124,710,628,837,000$1,567,538,259,936,880,000.00$16,056$1,162.76+$1576124710628.82MVMCS
7$289,423,013,630,119,900,000$287,736,560,189,747,040,000.00$18,175$1,604.53+$289423013630119.88MVMCS
8$49,689,985,921,465,780,000,000$49,380,303,296,881,550,000,000.00$21,009$2,252.68+$49689985921465776.00MVMCS
9$7,976,462,589,593,958,000,000,000$7,923,294,304,657,990,000,000,000.00$24,911$3,229.73+$7976462589593958400.00MVMCS
10$1,197,210,746,187,382,400,000,000,000$1,188,675,931,216,516,700,000,000,000.00$30,458$4,749.88+$1.1972107461873825e+21MVMCS

VMCS vs JNJ: Complete Analysis 2026

VMCSStock

InnovaQor, Inc. develops and provides information technology solutions and services to healthcare and laboratory customers in the United States. It offers electronic health records product for behavioral health providers and substance abuse centers, as well as a related product for ambulatory practices; and laboratory information system product for small to mid-size clinical laboratories. The company also develops business intelligence and aggregated data analytics in real-time to allow decision support. In addition, it provides virtual chief information officer (vCIO) services, such as life-cycle project and program management services; consulting, and outsourced product design, development, enhancement, and testing services; and IT managed services, such as backups and diagnostics tools to identify breaks in security and solutions, as well as designs and implements security policies, solutions that integrate physical surveillance and access control to cyber security, and systems. The company was formerly known as VisualMED Clinical Solutions Corp. and changed its name to InnovaQor, Inc. in September 2021. InnovaQor, Inc. was founded in 1999 and is based in West Palm Beach, Florida.

Full VMCS Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VMCS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VMCS vs SCHDVMCS vs JEPIVMCS vs OVMCS vs KOVMCS vs MAINVMCS vs ABBVVMCS vs MRKVMCS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.